Annual financial results as of 31 December, 2021
29/04/2022 – AB Science reports its revenues for the year 2021 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19
28/04/2022 – AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)
29/03/2022 – AB Science acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading.
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
28/02/2022 – Presentation of the webcast held on February 28, 2022 on masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
24/02/2022 – AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications
Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
22/02/2022 – AB Science announced the publication of results from its positive pivotal phase 3 trial of masitinib in progressive forms of multiple sclerosis in the peer-reviewed journal Neurology® Neuroimmunology & Neuroinflammation
Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
21/02/2022 – AB Science today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy
Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)
12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022
AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit
07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit